Abstract
Twenty-eight myelodysplastic syndromes (MDS) patients were treated with arsenic trioxide (ATO) and thalidomide. Seven patients responded including one complete hematologic and cytogenetic response and one with regression in spleen size. Two trilineage responses were seen in patients with inv(3)(q21q26.2). Three of five patients who had high pre-therapy EVI1 levels showed unexpectedly good responses while two died early in the first cycle. In vitro studies using 32Dcl3 cells forced to express EVI1 confirmed increased sensitivity of these cells to ATO. Both low/high risk MDS may benefit significantly from therapy with ATO/thalidomide, and those with high pre-therapy EVI1 expression may be uniquely sensitive.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Arsenic Trioxide
-
Arsenicals / therapeutic use*
-
Cell Lineage
-
DNA-Binding Proteins / genetics
-
DNA-Binding Proteins / metabolism*
-
Drug Resistance, Neoplasm*
-
Drug Therapy, Combination
-
Female
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
MDS1 and EVI1 Complex Locus Protein
-
Male
-
Middle Aged
-
Myelodysplastic Syndromes / drug therapy*
-
Myelodysplastic Syndromes / pathology
-
Oxides / therapeutic use*
-
Proto-Oncogenes*
-
Reverse Transcriptase Polymerase Chain Reaction
-
Risk Factors
-
Spleen / metabolism
-
Spleen / pathology
-
Thalidomide / therapeutic use*
-
Transcription Factors*
-
Zinc Fingers
Substances
-
Antineoplastic Agents
-
Arsenicals
-
DNA-Binding Proteins
-
Immunosuppressive Agents
-
MDS1 and EVI1 Complex Locus Protein
-
MECOM protein, human
-
Oxides
-
Transcription Factors
-
Thalidomide
-
Arsenic Trioxide